Is Rivian a Good Stock a Buy?
Rivian Automotive (RIVN) had an initial IPO of close to…
Buy
86
XERS Quote, Financials, Valuation and Earnings
Last price:
$5.87
Seasonality move
:
52.1%
Day range:
$5.64 - $5.97
52-week range:
$1.69 - $5.92
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.20x
P/B ratio:
--
Volume:
6.3M
Avg. volume:
3.2M
1-year change:
179.52%
Market cap:
$894.4M
Revenue:
$203.1M
EPS (TTM):
-$0.38
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
XERS
Xeris Biopharma Holdings
|
$58.5M | -$0.02 | 41.76% | -71.43% | $6.08 |
|
ADMA
ADMA Biologics
|
$112.8M | $0.15 | 42.17% | 75% | $25.27 |
|
CARA
Cara Therapeutics
|
$1.6M | -$2.94 | -73.37% | -83.05% | $12.00 |
|
OCGN
Ocugen
|
$300K | -$0.05 | -100% | -- | $6.75 |
|
OCUL
Ocular Therapeutix
|
$16.9M | -$0.22 | 16.58% | -42.86% | $17.45 |
|
TGTX
TG Therapeutics
|
$100.7M | $0.20 | 84.44% | -95.36% | $42.83 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
XERS
Xeris Biopharma Holdings
|
$5.81 | $6.08 | $894.4M | -- | $0.00 | 0% | 4.20x |
|
ADMA
ADMA Biologics
|
$20.32 | $25.27 | $4.8B | 24.78x | $0.00 | 0% | 11.57x |
|
CARA
Cara Therapeutics
|
$5.62 | $12.00 | $25.7M | -- | $0.00 | 0% | 3.59x |
|
OCGN
Ocugen
|
$0.64 | $6.75 | $186.1M | -- | $0.00 | 0% | 42.59x |
|
OCUL
Ocular Therapeutix
|
$7.62 | $17.45 | $1.2B | -- | $0.00 | 0% | 18.92x |
|
TGTX
TG Therapeutics
|
$42.61 | $42.83 | $6.7B | 304.36x | $0.00 | 0% | 20.29x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
XERS
Xeris Biopharma Holdings
|
114.63% | 1.265 | 45.82% | 1.12x |
|
ADMA
ADMA Biologics
|
17.17% | 4.789 | 1.78% | 2.76x |
|
CARA
Cara Therapeutics
|
-- | -3.732 | -- | 10.67x |
|
OCGN
Ocugen
|
49.18% | 4.395 | 12.22% | 2.71x |
|
OCUL
Ocular Therapeutix
|
17.85% | 3.384 | 5.09% | 10.26x |
|
TGTX
TG Therapeutics
|
52.36% | 3.612 | 5.21% | 4.85x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
XERS
Xeris Biopharma Holdings
|
$50.6M | $1.7M | -26.85% | -1019.2% | 4.31% | $1.8M |
|
ADMA
ADMA Biologics
|
$63.3M | $38.3M | 60.85% | 93.41% | 31.98% | $47.5M |
|
CARA
Cara Therapeutics
|
$1.5M | -$5.5M | -374.56% | -374.56% | -374.98% | -$4M |
|
OCGN
Ocugen
|
-- | -$13.8M | -136.46% | -171.04% | -1811.52% | -$10.4M |
|
OCUL
Ocular Therapeutix
|
$15.9M | -$50.6M | -51.22% | -62.66% | -265.09% | -$39.6M |
|
TGTX
TG Therapeutics
|
$92.8M | $29.9M | 6.86% | 12.81% | 30.05% | -$25.7M |
Xeris Biopharma Holdings vs. Competitors
-
Which has Higher Returns XERS or ADMA?
ADMA Biologics has a net margin of -8.51% compared to Xeris Biopharma Holdings's net margin of 95.19%. Xeris Biopharma Holdings's return on equity of -1019.2% beat ADMA Biologics's return on equity of 93.41%.
Company Gross Margin Earnings Per Share Invested Capital XERSXeris Biopharma Holdings84.23% -$0.03 $202.5M ADMAADMA Biologics53.88% $0.46 $421.4M -
What do Analysts Say About XERS or ADMA?
Xeris Biopharma Holdings has a consensus price target of $6.08, signalling upside risk potential of 7.57%. On the other hand ADMA Biologics has an analysts' consensus of $25.27 which suggests that it could grow by 24.37%. Given that ADMA Biologics has higher upside potential than Xeris Biopharma Holdings, analysts believe ADMA Biologics is more attractive than Xeris Biopharma Holdings.
Company Buy Ratings Hold Ratings Sell Ratings XERSXeris Biopharma Holdings4 1 0 ADMAADMA Biologics4 0 0 -
Is XERS or ADMA More Risky?
Xeris Biopharma Holdings has a beta of 1.615, which suggesting that the stock is 61.462% more volatile than S&P 500. In comparison ADMA Biologics has a beta of 0.605, suggesting its less volatile than the S&P 500 by 39.509%.
-
Which is a Better Dividend Stock XERS or ADMA?
Xeris Biopharma Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xeris Biopharma Holdings pays -- of its earnings as a dividend. ADMA Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XERS or ADMA?
Xeris Biopharma Holdings quarterly revenues are $60.1M, which are smaller than ADMA Biologics quarterly revenues of $117.5M. Xeris Biopharma Holdings's net income of -$5.1M is lower than ADMA Biologics's net income of $111.9M. Notably, Xeris Biopharma Holdings's price-to-earnings ratio is -- while ADMA Biologics's PE ratio is 24.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xeris Biopharma Holdings is 4.20x versus 11.57x for ADMA Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XERSXeris Biopharma Holdings4.20x -- $60.1M -$5.1M ADMAADMA Biologics11.57x 24.78x $117.5M $111.9M
-
Which has Higher Returns XERS or CARA?
Cara Therapeutics has a net margin of -8.51% compared to Xeris Biopharma Holdings's net margin of -527.77%. Xeris Biopharma Holdings's return on equity of -1019.2% beat Cara Therapeutics's return on equity of -374.56%.
Company Gross Margin Earnings Per Share Invested Capital XERSXeris Biopharma Holdings84.23% -$0.03 $202.5M CARACara Therapeutics70.96% -$1.73 -$4.6M -
What do Analysts Say About XERS or CARA?
Xeris Biopharma Holdings has a consensus price target of $6.08, signalling upside risk potential of 7.57%. On the other hand Cara Therapeutics has an analysts' consensus of $12.00 which suggests that it could grow by 113.52%. Given that Cara Therapeutics has higher upside potential than Xeris Biopharma Holdings, analysts believe Cara Therapeutics is more attractive than Xeris Biopharma Holdings.
Company Buy Ratings Hold Ratings Sell Ratings XERSXeris Biopharma Holdings4 1 0 CARACara Therapeutics0 1 0 -
Is XERS or CARA More Risky?
Xeris Biopharma Holdings has a beta of 1.615, which suggesting that the stock is 61.462% more volatile than S&P 500. In comparison Cara Therapeutics has a beta of 0.499, suggesting its less volatile than the S&P 500 by 50.057%.
-
Which is a Better Dividend Stock XERS or CARA?
Xeris Biopharma Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cara Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xeris Biopharma Holdings pays -- of its earnings as a dividend. Cara Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XERS or CARA?
Xeris Biopharma Holdings quarterly revenues are $60.1M, which are larger than Cara Therapeutics quarterly revenues of $1.5M. Xeris Biopharma Holdings's net income of -$5.1M is higher than Cara Therapeutics's net income of -$7.7M. Notably, Xeris Biopharma Holdings's price-to-earnings ratio is -- while Cara Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xeris Biopharma Holdings is 4.20x versus 3.59x for Cara Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XERSXeris Biopharma Holdings4.20x -- $60.1M -$5.1M CARACara Therapeutics3.59x -- $1.5M -$7.7M
-
Which has Higher Returns XERS or OCGN?
Ocugen has a net margin of -8.51% compared to Xeris Biopharma Holdings's net margin of -1816.75%. Xeris Biopharma Holdings's return on equity of -1019.2% beat Ocugen's return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital XERSXeris Biopharma Holdings84.23% -$0.03 $202.5M OCGNOcugen-- -$0.05 $58.3M -
What do Analysts Say About XERS or OCGN?
Xeris Biopharma Holdings has a consensus price target of $6.08, signalling upside risk potential of 7.57%. On the other hand Ocugen has an analysts' consensus of $6.75 which suggests that it could grow by 958.99%. Given that Ocugen has higher upside potential than Xeris Biopharma Holdings, analysts believe Ocugen is more attractive than Xeris Biopharma Holdings.
Company Buy Ratings Hold Ratings Sell Ratings XERSXeris Biopharma Holdings4 1 0 OCGNOcugen2 0 0 -
Is XERS or OCGN More Risky?
Xeris Biopharma Holdings has a beta of 1.615, which suggesting that the stock is 61.462% more volatile than S&P 500. In comparison Ocugen has a beta of 3.883, suggesting its more volatile than the S&P 500 by 288.285%.
-
Which is a Better Dividend Stock XERS or OCGN?
Xeris Biopharma Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xeris Biopharma Holdings pays -- of its earnings as a dividend. Ocugen pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XERS or OCGN?
Xeris Biopharma Holdings quarterly revenues are $60.1M, which are larger than Ocugen quarterly revenues of $764K. Xeris Biopharma Holdings's net income of -$5.1M is higher than Ocugen's net income of -$13.9M. Notably, Xeris Biopharma Holdings's price-to-earnings ratio is -- while Ocugen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xeris Biopharma Holdings is 4.20x versus 42.59x for Ocugen. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XERSXeris Biopharma Holdings4.20x -- $60.1M -$5.1M OCGNOcugen42.59x -- $764K -$13.9M
-
Which has Higher Returns XERS or OCUL?
Ocular Therapeutix has a net margin of -8.51% compared to Xeris Biopharma Holdings's net margin of -283.27%. Xeris Biopharma Holdings's return on equity of -1019.2% beat Ocular Therapeutix's return on equity of -62.66%.
Company Gross Margin Earnings Per Share Invested Capital XERSXeris Biopharma Holdings84.23% -$0.03 $202.5M OCULOcular Therapeutix92.8% -$0.29 $383.8M -
What do Analysts Say About XERS or OCUL?
Xeris Biopharma Holdings has a consensus price target of $6.08, signalling upside risk potential of 7.57%. On the other hand Ocular Therapeutix has an analysts' consensus of $17.45 which suggests that it could grow by 129.06%. Given that Ocular Therapeutix has higher upside potential than Xeris Biopharma Holdings, analysts believe Ocular Therapeutix is more attractive than Xeris Biopharma Holdings.
Company Buy Ratings Hold Ratings Sell Ratings XERSXeris Biopharma Holdings4 1 0 OCULOcular Therapeutix5 0 0 -
Is XERS or OCUL More Risky?
Xeris Biopharma Holdings has a beta of 1.615, which suggesting that the stock is 61.462% more volatile than S&P 500. In comparison Ocular Therapeutix has a beta of 1.337, suggesting its more volatile than the S&P 500 by 33.685%.
-
Which is a Better Dividend Stock XERS or OCUL?
Xeris Biopharma Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocular Therapeutix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xeris Biopharma Holdings pays -- of its earnings as a dividend. Ocular Therapeutix pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XERS or OCUL?
Xeris Biopharma Holdings quarterly revenues are $60.1M, which are larger than Ocular Therapeutix quarterly revenues of $17.1M. Xeris Biopharma Holdings's net income of -$5.1M is higher than Ocular Therapeutix's net income of -$48.4M. Notably, Xeris Biopharma Holdings's price-to-earnings ratio is -- while Ocular Therapeutix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xeris Biopharma Holdings is 4.20x versus 18.92x for Ocular Therapeutix. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XERSXeris Biopharma Holdings4.20x -- $60.1M -$5.1M OCULOcular Therapeutix18.92x -- $17.1M -$48.4M
-
Which has Higher Returns XERS or TGTX?
TG Therapeutics has a net margin of -8.51% compared to Xeris Biopharma Holdings's net margin of 21.57%. Xeris Biopharma Holdings's return on equity of -1019.2% beat TG Therapeutics's return on equity of 12.81%.
Company Gross Margin Earnings Per Share Invested Capital XERSXeris Biopharma Holdings84.23% -$0.03 $202.5M TGTXTG Therapeutics85.77% $0.15 $466.8M -
What do Analysts Say About XERS or TGTX?
Xeris Biopharma Holdings has a consensus price target of $6.08, signalling upside risk potential of 7.57%. On the other hand TG Therapeutics has an analysts' consensus of $42.83 which suggests that it could grow by 0.52%. Given that Xeris Biopharma Holdings has higher upside potential than TG Therapeutics, analysts believe Xeris Biopharma Holdings is more attractive than TG Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings XERSXeris Biopharma Holdings4 1 0 TGTXTG Therapeutics5 0 0 -
Is XERS or TGTX More Risky?
Xeris Biopharma Holdings has a beta of 1.615, which suggesting that the stock is 61.462% more volatile than S&P 500. In comparison TG Therapeutics has a beta of 2.303, suggesting its more volatile than the S&P 500 by 130.31%.
-
Which is a Better Dividend Stock XERS or TGTX?
Xeris Biopharma Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xeris Biopharma Holdings pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XERS or TGTX?
Xeris Biopharma Holdings quarterly revenues are $60.1M, which are smaller than TG Therapeutics quarterly revenues of $108.2M. Xeris Biopharma Holdings's net income of -$5.1M is lower than TG Therapeutics's net income of $23.3M. Notably, Xeris Biopharma Holdings's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 304.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xeris Biopharma Holdings is 4.20x versus 20.29x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XERSXeris Biopharma Holdings4.20x -- $60.1M -$5.1M TGTXTG Therapeutics20.29x 304.36x $108.2M $23.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Chevron Acquire Hess?
Long-time Buffett favorite in the energy sector Chevron (NYSE:CVX) is…
Why Did Progressive Stock Go Down?
Shares of insurance giant Progressive (NYSE:PGR) have fallen considerably over…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3T
P/E Ratio: 41x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Sell
47
RGC alert for Mar 25
Regencell Bioscience Holdings [RGC] is up 4.9% over the past day.
Buy
54
AZEK alert for Mar 25
The AZEK [AZEK] is up 1.01% over the past day.
Sell
36
MPTI alert for Mar 25
M-Tron Industries [MPTI] is up 7.48% over the past day.
